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Method: The CIED was a one-time survey initiated by the Indian
Society of Electrocardiology (ISE) and the Indian Heart Rhythm
Society (IHRS). The device survey forms were distributed to im-
planters across many centres in India. A total of 2117 device sur-
vey forms from 136 centres were collected from April 2012 to
March 2013.
Results: Pacemaker constituted almost 80% of the devices
implanted in India. The CIED were more frequently implanted in
males (64%) and in the sixth and seventh decade of life (51%).
Complete atrio-ventricular (AV) block was the indication of
pacemaker implantation in almost 80% of the patients. 54% pa-
tients received a single chamber pacemaker. In the ICD group
(10%), single chamber ICD was used in 65%; as a primary pro-
phylaxis indication in 52.5% and most often implanted in patients
with coronary artery disease (CAD). In theCRT group (10%), CRT-P
was used in 57% of these patients, 82% were in NYHA class III or
more and the left ventricular ejection fraction (LVEF) < 0.35 in 88%
of the patients.
Conclusion: Bradycardia pacemakers are the most common CIED
implanted in India with complete AV block being the indication in
vastmajority. In the ICD group, single chamber device was used in
two-thirds of the patients and primary prophylaxis use of ICD was
common. CRT-P devices were mainly used in patients with NYHA
III or more and LVEF < 0.35 or less.
Prognosis of drug-induced atrioventricular block
A.K. Boro, P.K. Gupta, H. Rahman, K.C. Narzary, S.K.S. Boro
GNRC Hospitals, Guwahati, India
Background: PM implantation is usually not considered in drug
related bradyarrhythmia (DRB). However, it is not clear whether
AV block is really caused by drugs or it merely exposes an un-
derlying AV conduction disease.
Methods: We prospectively studied 72 consecutive patients (66±
12 yrs, 42% women) with DRB (b-blockers, calcium channel
blockers and digitalis ) between February 2009 & march 2014.Pa-
tients with symptomatic type II 2 or 3 AV block ,2:1 AV block,
sinus bradycardia  40/min, AF with average V rate  40/min or
pause >5 secs were included in the study. Patients were excluded
if their AV block was attributed to acute MI, electrolyte imbal-
ances, digitalis toxicity and other antiarrhythmic drugs. Patients
were classified into 3 groups:1. DRB resolved after the discontin-
uation of culprit drug 2.DRB persisted after drug withdrawal or
recurred after initial resolution 3.DRB with undetermined corre-
lation: PM implanted and medication continued. The mean
follow-up duration was 16 ± 9 months.
Results: The level of AVB was infranodal in 51%, AV-nodal in 37 %
& undetermined in 12%. Drug discontinuation was followed by
resolution of AV block in 57% patients. However, 37 % patients
with resolution of AVB had recurrence in the absence of culprit
drug. Six patients had early recurrence during index hospitaliza-
tion. In 31% AVB persisted even after the discontinuation of
drugs.PM was implanted in all patients with persistent or recur-
rent AVB despite withdrawal of drug. Two patients with DRB-
undetermined relation underwent pacemaker implantation and
the medication continued. Thirty five patients with resolution of
AV block were discharged & followed up for an average of 16± 9
months. Two patients died and 9 patients had recurrence of AV
block in the absence of the culprit drugs.
Conclusions: Half of our patients (54%) with DRB had persistent
indication for PMevenafterwithdrawal ofAVblockers. PossiblyAV
blocking drugs merely exposed underlying AV conduction defect.
Ivabradine in AV nodal disease on dual chamber
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Background: The use of ivabradine as a rate reducing drug is well
documented. In normotensive individuals and those with
obstructive airway disease, the use of other rate reducing drugs
like beta blockers and calcium channel blockers have limitations.
Patients with AV nodal disease can have high atrial rates when
they have a dual chamber pacemaker implanted. The high atrial
rates are translated into high ventricular rates as the atrium is
tracked and ventricle is paced, often at the upper tracking rate
which is undesirable for the patient. The study focuses on the
novel use of ivabradine in reducing the atrial rate in patients with
AV nodal disease on dual chamber pacing.
Methods: During a 2 year period from July 2011 to July 2013, 85
patients with A-V block had dual chamber pacemaker implanted.
Within 3 months of implantation 12 patients presented with
palpitation. All the patients were on dual chamber rate respon-
sive pacemaker (DDDR). All of them had AV nodal disease
ecomplete AV dissociation in 8 and high degree AV block in 4
patients. On interrogation, all of them had high atrial rate epi-
sodes ranging from 90 to 116 beats per minute. Patients were put
on ivabradine 5mg twice daily in 8 patients and 7.5mg twice daily
in 4 patients.
Results: Out of the 12 patients, 9 were females and 3 weremales. 7
patients were diabetics. Obstructive airway disease in 5 and 3 of
them were hypertensive. The average incidence of ventricular
pacing was 96%. Atrial sensed ventricular pacing (AS-vp) was
noted on interrogation in11/12 patients (91.6%) Atrial paced ven-
tricular sensing (as-vp) in 1 patient .The patients could not
tolerate betablockers or calcium channel blockers. The average
ventricular pacing rate before ivabradine was 96/min(82-104- 96%
CI).The average dose of Ivabradine was 5mg twice a day in 8
patients(66%).In 4 patients the dosage requirement was 7.5mg
twice a day(33%).After administration of ivabradine ,the the
average pacing rate reduced significantly in all the patients. The
average rate of ventricular pacing was 80/min (76- 84- 98%CI) (p
<0.05) which was significantly less than the pre ivabradine rate.
Conclusion: The administration of ivabradine in patients on dual
chamber pacemaker with high atrial rates significantly reduces
the atrial rate and reduces the rate of atrial tracked ventricular
pacing.
Busting the myth of ventricular dysfunction
secondary to dyssynchrony in WPW syndromes
A.A. Cheriyan, P. Kamath, C. Rajiv
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Background: Ventricular dyssynchrony has been held responsible
for impaired LV function in pre-excitation syndromes especially
with left sided and posteroseptal accessory pathways (APs) due to
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